Russian Doctors and other Professionals Are Needed To Expose Drug Bribes: Russians Can Confidentially Expose Illegal Drug Company Bribery Schemes Through a Lawyer and Collect Large Financial Rewards by International Foreign Corrupt Practices Act Whistleblower Reward Lawyer Jason S. Coomer
Russians can receive large financial rewards for confidentially exposing illegal pharmaceutical company bribes to Russian doctors, health administrators, and other government officials. Persons that are aware of and have evidence of illegal drug company bribes are encouraged to contact a Foreign Corrupt Practices Act Whistleblower reward Lawyer to review a potential bounty action.
If you are a Russian doctor or other Russian public health official and are aware of an illegal bribery scheme by a drug company and are interested in a confidential review of a whistleblower bounty action, please feel free to contact Russian Drug Company Bribe Whistleblower Reward Lawyer Jason Coomer via e-mail message or use our submission form.
The Foreign Corrupt Practices Act
The Foreign Corrupt Practices Act (FCPA) prohibits bribery of foreign officials by U.S. and foreign companies listed on the U.S. securities exchange. Foreign Corrupt Practices Act Whistleblowers that properly report violations of the FCPA by a U.S. or foreign company listed on the U.S. securities exchanges can recover a large reward for exposing FCPA violations. These whistleblowers can expose bribery schemes through a lawyer and protect their identify.
The Russian Drug Market is Rapidly Expanding Creating Increased Competition and Corruption
The Russian pharmaceutical market is attracting increasing global interest because its value is expected to triple within the next decade making the ability to influence and control Russian doctors critical to gaining control of this rapidly growing market and obtaining long-term profits. Under the Fundamentals of Protection of Public Health in the Russian Federation, Russian doctors are now tasked with creating treatment protocols and defining Essential Drug Lists (EDL). These lists will form the basis of new reimbursement plans and treatment guidelines that will be rolled out across the regions over the next several years. As such, some pharmaceutical companies are offering illegal bribes to influence Russian doctors and other Russian public health officials to include their drugs in treatment guidelines and reimbursement guidelines.
Drug Company Bribes in China, Brazil, Russia, India, Venezuela, Poland and Ukraine for Procurement Contracts Are Becoming More Common And Can Be The Basis For Large Bounty Action Rewards
Every year over $4.1 trillion (US dollars) is spent worldwide on health services including approximately $850 billion (US dollars) that is spent in the pharmaceutical market on drugs and medications. In 2011, it is estimated that global pharmaceutical sales are expected to grow by 5% to 7% to around $880 billion. This growth in sales is led by the 17 so-called "pharmerging countries," which include China, Brazil, Russia, India, Venezuela, Poland, and Ukraine. These "pharmerging countries", are forecast to see their pharmaceutical spending grow at a 15% to 17% rate in 2011, to between $170 billion and $180 billion overall.
Eight pharmerging countries are amongst the top 20 world pharmaceutical markets, and China is one of the “top three” or will be in the near future. A few high-profile pharmaceutical companies have been successful in gaining a foothold in these pharmering countries. These footholds include Abbott’s acquisition of Piramal Healthcare in India — a deal that could potentially make the US giant the top player in this country. Bayer's and Novartis' investments in China including Novartis' commitment to invest $1 billion USD in R&D in China and its $125 million USD investment to buy 85 percent stake in a privately held vaccine company. Pfizer has made inroads into the Russian health care system with a discount-card system in Russia Sanofi Aventis has purchased Medley, Brazil’s third-largest pharmaceutical company. GSK and Lilly have also announced anticipated doubling their revenue in emerging markets by 2015.
It is estimated that approximately 10 to 25% of public health care procurement spending including drug contracts, medicine purchases, and pharmaceutical contracts are lost to corrupt and fraudulent acts. As such, there is an international movement to reward pharmaceutical professionals and health care professionals that expose fraudulent and corrupt practices that cost hundreds of billions of dollars and cost lives. This international movement includes SEC Foreign Corrupt Practices Act Whistleblower Reward Lawsuits and traditional Qui Tam False Claims Act Whistleblower Reward Lawsuits.
Foreign Corrupt Practices Act Whistleblower Rewards
Under the Foreign Corrupt Practices Act and the new SEC Whistleblower Incentive Program, whistleblowers with original and specialized knowledge and evidence of corporate bribery and illegal kickbacks are eligible to recover large economic awards. By gathering this evidence and going through a lawyer, these whistleblowers can protect their identity through the process and potentially collect large rewards of 10% to 30% of the monetary sanctions including disgorged funds. If you are aware of an illegal bribe or illegal kickback that was used to secure a large contract, please feel free to contact International Whistleblower Lawyer Jason Coomer via e-mail message or use our submission form about a potential SEC Whistleblower Incentive Program Action or other Whistleblower Bounty Action.
Foreign Corrupt Practices Act Whistleblower Laws Apply to All Foreign and U.S. Companies Listed on the U.S. Securities Exchanges as well as their Subsidiaries, Joint Venture Partners, and Agents
The Foreign Corrupt Practices Act (FCPA) applies to “issuers” (U.S. and foreign companies listed on U.S. securities exchanges and their employees); “domestic concerns,” which run the gamut of business entities organized under U.S. laws or with their principal place of business in the United States; the officers, directors, employees, and agents of those U.S. business entities (irrespective of nationality); U.S. citizens; U.S. resident aliens; “any person,” including all foreign persons, who commit an act in furtherance of a foreign bribe while in the United States, and U.S. businesses and nationals acting abroad. A Company must require all of its affiliated companies and all of their employees to comply with the Foreign Corrupt Practices Act.
SEC Whistleblower Incentive Program Information
Corporations that pay illegal kickbacks and bribes to government officials and former government officials in exchange for contracts including large building projects can be brought to justice and made to pay large penalties under the Foreign Corrupt Practices Act and whistleblowers that bring these corporations to justice may be able to collect large economic rewards under the Securities Exchange Act (SEC Whistleblower Bounty Actions) and the Commodity Exchange Act (CFTC Whisteblower Bounty Actions).
The Illegal Bribe Whistleblower or Illegal Kickback Whistleblower may be entitled to not only the amount of the illegal bribe or kickback, but the benefit of the illegal bribe or kickback. In cases where $100,000.00 bribe is made to obtain a $100 million building project, the Illegal Bribe Whistleblower or Illegal Kickback Whistleblower may be entitled to 10 to 30% of the $100,000,000.00 and the $100,000.00 translating into a $10 million to $30 million award.
Johnson & Johnson Bribery Lawsuit
According to Bloomberg news, "Johnson & Johnson (JNJ), the world’s second-biggest seller of medical products, will pay $70 million after admitting that the company bribed doctors in Europe and paid kickbacks in Iraq to win contracts and sell drugs and artificial joints." Johnson & Johnson Will Pay $70 Million Over Bribery Claims By Joshua Gallu and Alex Nussbaum - Apr 8, 2011 2:09 PM CT
The SEC Complaint alleges that Johnson & Johnson through subsidiaries paid bribes to key health care provider decision makers including doctors and hospital administrators in several countries to win large contracts under the U.N. oil-for-food program. Further, the SEC alleged that Johnson & Johnson used slush funds, sham contracts and off-shore companies to carry out large bribes to key medical decision makers to secure large contracts and reward these decision makers for selecting Johnson & Johnson.
"The company agreed to pay $48.6 million in disgorgement and interest to settle the SEC’s claims and a $21.4 million fine to settle criminal charges filed by the Justice Department. As part of a deferred prosecution agreement with Justice, J&J admitted to the allegations and agreed to report on remediation and compliance measures every six months for three years." Johnson & Johnson Will Pay $70 Million Over Bribery Claims By Joshua Gallu and Alex Nussbaum - Apr 8, 2011 2:09 PM CT
Foreign Corrupt Practices Act Lawyer Jason S. Coomer
As an International Whistleblower Foreign Corrupt Practices Act Lawyer and SEC International Business Whistleblower Reward Lawyer, Jason S. Coomer commonly works with other powerful international business lawyers to handle large International Lawsuits dealing with whistleblowers and illegal bribes, kickbacks, fraud and other SEC Foreign Corrupt Practices Act Lawsuits He also works on Medicare Fraud Whistleblower Lawsuits, Defense Contractor Fraud Whistleblower Lawsuits, Stimulus Fraud Whistleblower Lawsuits, Government Contractor Fraud Whistleblower Lawsuits, Medicare Illegal Kickback Lawsuits, Confidential Financial Analyst Whistleblower Reward Lawsuits and other whistleblower recovery lawsuits.
If you are the original source with special knowledge of fraud and are interested in learning more about a potential lawsuit please feel free to contact Lawyer Jason Coomer via e-mail message or use our submission form